Medical News | Australian Researcher: Triple Therapy (Ivermectin, Zinc, Doxycycline) for COVID-19

   

TrialSite News

 

Published on Aug 17, 2020

Well-Respected Australian Researcher: Consider Triple Therapy (#Ivermectin, Zinc, #Doxycycline) for COVID-19:
Thomas Borody touts FDA and Australian food and drug authority TGA approved Ivermectin, which he reports to use regularly in his hospital as it evidences positive results for #COVID19 and should be used immediately to fight the pandemic. The developer of the world’s first cure for peptic ulcers, which saved millions of lives worldwide, employed the same methodology to come up with the Ivermectin triple therapy. With over 30 formal clinical trials, many dozens of observational real-world initiatives and hundreds to possibly thousands of doctors already using the medicine, a particular momentum gains speed for additional randomized controlled trials and, just as importantly, a more serious dialogue about the potential of this approach for pragmatic and economical treatment options for COVID-19.
https://www.trialsitenews.com/well-respected-australian-researcher-consider-triple-therapy-ivermectin-zinc-doxycycline-for-covid-19/

 
TrialSite News Documentary:

TrialSite have produced a documentary on this very topic in South America and will be releasing it to the public by this Friday. In this TrialSite production out of Peru we take an objective probe into the situation in Peru: how did Ivermectin become approved as a drug targeting COVID-19? What data was used as evidence to validate such a decision? Has consensus been met there on the approval or is there debate?
https://youtu.be/vzO_9TX5vXc

RLF-100 (Aviptadil) Associated with Rapid Respiratory Failure Recovery Among COVID-19 Patients:
Last week we touched on this subject of RLF-100 and this week, we’ll continue to expand on this story. NeuroRX, Inc. and Relief Therapeutics Holdings AG announced that the investigational therapy RLF-100 (Aviptadil) showed evidence of rapid recovery from respiratory failure in the most critically ill patients with COVID-19. In parallel, an independent group of researchers have reported that Aviptadil blocked replication of SARS-CoV-2 in human lung cells and monocytes. The drug has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies.
https://www.trialsitenews.com/rlf-100-aviptadil-associated-with-rapid-respiratory-failure-recovery-among-covid-19-patients/

Russia’s Gamaleya Vaccine Approved by Russian Health Authorities:
The Russian Health Ministry has approved the world’s first COVID-19 vaccine after fewer than two months of formal human clinical trials. TrialSite News has been following the Gamaleya National Research Institute of Epidemiology and Microbiology (Gamaleya Institute) vaccine effort, and it is suspected that the Russians introduced some form of intensive human challenge trial that started with scientists and perhaps military personnel and then included broader groups, even an elite “VIP” group cohort. Now Russia’s President, Vladimir Putin, proudly declared to all via a televised video conference call with government ministers: “This morning, for the first time in the word, a vaccine against the new coronavirus was registered” in Russia. Putin, in anticipation of the critics, emphatically declared, “I would like to repeat that it has passed all the necessary tests.”
https://www.trialsitenews.com/gamaleya-vaccine-approved-in-unprecedented-race-to-approved-vaccine-did-russia-win/

The Need for Convalescent Plasma in TN:
Research is proving convalescent plasma can help those that have COVID-19 recover faster. However, Ballad Health is having to outsource plasma from other regions due to a lack in local donations, but one Northeast Tennessee native is making the most of an unfortunate situation.
https://www.trialsitenews.com/the-need-for-convalescent-plasma-in-tn/